Key result
Captopril-stimulated renal vein renin ratio poorly predicts revascularization response, with only ~65% sensitivity.
Why the study?
The ability of the captopril-stimulated renal vein renin ratio to identify patients with hemodynamically significant renovascular lesions who would respond to revascularization was uncertain.
Does the captopril-stimulated renal vein renin ratio (CSRVRR) accurately predict blood pressure response to revascularization in patients with suspected renovascular hypertension?
Cohort (n=143)
Does the captopril-stimulated renal vein renin ratio (CSRVRR) accurately predict blood pressure response to revascularization in patients with suspected renovascular hypertension?
The captopril-stimulated renal vein renin ratio lacks sufficient sensitivity (65%) and specificity (47.8% false-positive rate) to reliably predict which hypertensive patients will respond to renal revascularization.
Answers are grounded in this paper and cite their sources.
CSRVRR >1.5 should not guide revascularization decisions; leaves open the need for reliable predictors in renovascular hypertension.
To determine whether the captopril-stimulated renal vein renin ratio (CSRVRR) could enable identification of patients with hemodynamically significant renovascular lesions who would respond to revascularization, the authors measured CSRVRRs in 143 consecutive patients with hypertension who had been selected because of clinical features suggestive of renovascular hypertension. All patients underwent conventional renal arteriography. Renovascular hypertension was the final diagnosis if revascularization resulted in cure or improvement in blood pressure. Complete data were available for 133 patients. Twenty patients had renovascular hypertension; CSRVRR was greater than 1.5 in 13 of these 20 patients (sensitivity, 65%). However, it was also greater than 1.5 in 54 of the 113 patients without renovascular hypertension (false-positive rate, 47.8%). The positive predictive value of CSRVRR was 18.6%; the negative predictive value, 89.3%. It is concluded that CSRVRR is not sufficiently sensitive to enable prediction of which patients will respond to revascularization and is not specific enough to exclude patients who do not have renovascular hypertension.
No takes yet. Share an insight, caveat, or question.
Roubidoux et al. (1991) conducted a cohort in Hypertension with clinical features suggestive of renovascular hypertension (n=143). Captopril-stimulated renal vein renin ratio (CSRVRR) > 1.5 vs. Conventional renal arteriography and blood pressure response to revascularization was evaluated on Renovascular hypertension (defined as cure or improvement in blood pressure following revascularization). Captopril-stimulated renal vein renin ratio >1.5 had only 65% sensitivity and a 47.8% false-positive rate for predicting blood pressure response to revascularization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: